Abstract: A movable capacitive sensing component and plural stationary capacitive sensing components are similarly constructed and are located together. The movable capacitive sensing component includes two interdigitated electrode elements at least one of which moves in accordance with displacement of an object. The stationary capacitive sensing components includes two interdigitated electrode elements that do not move, and differ from each other in terms of relative displacement between the fixed electrode elements. The movable capacitive sensing component measures a capacitance value. Another capacitance value is estimated, from the capacitance values measured by the stationary capacitive sensing components, for the displacement indicated by the movable capacitive sensing component's measured capacitance value.

Abstract: The isolation and characterization of a glucosyltransferase gene from Candida bombicola is disclosed. Use of the glucosyltransferase enzyme for the production of glucosylated sterol and hydroxyl-fatty acid substrates is also disclosed. This enzyme has broad-specificity and is useful for the production of sophorolipids both in-vivo and in-vitro.

Abstract: An antenna array includes a plurality of sub-arrays each having a plurality of linearly polarized antenna elements, with each antenna element having an orthogonal feed orientation with respect to its adjacent antenna elements, and at least two feed lines each connected by at least one sub-feed line to at least two antenna elements having orthogonal feed orientations such that each antenna element is equally and progressively phase rotated. The antenna elements in at least two separate lines of the array, such as array rows or columns, are connected to a separate feed line. The antenna elements may be aperture coupled microstrip patch elements having a single slot fed by one of the sub-feed lines or cross-slot elements fed by two sub-feed lines. The sub-feed lines in a separate row or column are power combined into either one or two feed lines and may be connected to a beamformer.

Abstract: Described is an isolated lignified plant cell wall including lignin, wherein the lignin includes a ferulate residue incorporated therein, such as from coniferyl ferulate and/or sinapyl ferulate. Also described is a method to make the isolated lignified plant cell wall, and the lignin produced by the method.

Abstract: A gas turbine engine that includes a compressor, a turbine, a heat exchanger, and a combustor. The compressor is mounted on a rotating shaft with at least one rotor with an inlet and an outlet, and at least one diffuser downstream from each rotor. The turbine includes at least one stator, and at least one rotor with an inlet and outlet located downstream of each stator, and mounted on the rotating shaft as the at least one of the compressor rotors. The inlet of the compressor rotor faces toward the outlet of the turbine rotor. The heat exchanger is configured to preheat the compressed air leaving the compressor by transferring heat from the turbine exhaust. The combustor can be configured for mixing fuel with the compressed air, either upstream or downstream from the heat exchanger, and further configured for igniting the preheated fuel/air mixture located downstream from the heat exchanger.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.

Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.

Abstract: An interleaving hexagonal tile (AHT) is provided for incorporation onto a liner in an array for a personnel armor clothing article. The AHT includes a hexagonally-symmetric solid object composed of a homogeneous material. The object includes a geometry that has obverse and reverse planar surfaces parallel to each other. Each planar surface has triangularly disposed terminals. First and second triple sets of oblique surfaces are disposed between the obverse and reverse planar surfaces. A plurality of facets is disposed substantially perpendicular to the planar surfaces. The facets connect between edges of the planar surfaces and adjacent edges of the oblique surfaces. The first and second triple sets of oblique surfaces are disposed to alternate with each other.

Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.

Abstract: The invention relates to a humanized nucleic acid construct from Bacillus anthracis protective antigen (PA) gene and method of modifying the gene. The humanized gene, and method of producing it, improves the structural fidelity of expressed protein product, when produced in mammalian host cells, to native, bacterially produced protein. The construct is useful in nucleic acid based vaccine formulations against B. anthracis.

Abstract: A system and method involve generating an electric field across a superconductor device having an ionic layer disposed between and separated from first and second superconductor layers by respective first and second barrier layers. The electric field may be generated by applying an input signal, such as a voltage, to the superconductor device while the device is in a superconducting state. The voltage may be below a threshold voltage for inducing ion transport within the ionic layer or may be above or below a threshold voltage for inducing ion transport from the ionic layer across an ionic layer/barrier layer interface. The ion transport may tune the potential profile and/or modulate the critical current of the superconductor device and may include quantum coherent ionic transport, Josephson tunneling, or resonant tunneling. The electric field generated across the superconductor device may alter the spin-states of the ions within the ionic layer.

Abstract: A system and method involve acoustic source localization using passive sonar and capitalizing on the sparse nature of a source location map (SLM). Two types of sparsity are exploited, namely sparsity in the support of the SLMs and sparsity in the innovations across consecutive SLMs. The first type is motivated by the desire to construct SLMs whose non-zero entries corresponded to locations where sources are present. The second type of sparsity is motivated by the observation that few changes occur in the support of consecutive SLMs. Per time instant, an SLM is obtained as the solution of a regularized least-squares problem, where the regularization terms are chosen to encourage the desired sparse structures in each SLM and the innovations. Each SLM may be obtained via a specifically-tailored, computationally-efficient proximal gradient algorithm.

Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.

Abstract: A method and apparatus for the water-based transfer of heavy loads. The invention is a lightweight apparatus is reconfigurable, and it includes a gantry arrangement mounted on beams or a platform and the apparatus is used to transfer heavy load items. The apparatus reconfigurable and may be used in a water-based loading environments in performing a variety of loading functions in situations involving one or more watercrafts and/or a pier or the like.

Abstract: A memory device comprising a base; a capacitor comprising a ferroelectric layer and at least two electrically conductive layers, the ferroelectric layer being located between the at least two electrically conductive layers; each of the at least two conductive layers being operatively connected to a current source; a cantilever attached to the base at first end and movable at a second end, the ferroelectric capacitor being mounted to the cantilever such that the second end of the cantilever moves a predetermined displacement upon application of a current to the ferroelectric layer which induces deformation of the ferroelectric layer thereby causing displacement of the cantilever which is operatively associated with a contact so that an electrical connection is enabled with the contact upon the predetermined displacement of the cantilever. The presence or absence of a connection forms two states of a memory cell.